Microalgal omega-3 (EPA/DHA algal oils)

01Overview and value chain#

Markers EC: EU Novel Food & FDA DSHEA dietary-supplement rules | OECD: Marine bioeconomy | Regulator: FDA (USA), EFSA (EU), NMPA (China)

Microalgal omega-3 is the industry that produces EPA and DHA lipid oils directly from microalgae, by-passing fish. dsm-firmenich’s life’sDHA® (from Crypthecodinium cohnii) is the global anchor for infant-formula and supplement DHA, and its 2026 life’sDHA® B54-0100 brings a naturally potent DHA algal oil with exceptional sensory appeal; Qualitas Health’s AlmegaPL® is a Nannochloropsis-derived EPA lecithin shown in a 2024 clinical trial to deliver superior omega-3 absorption; Fermentalg launched OMEGA ΩRIGINS™ high-EPA/DHA algal oil and posted a record €3.7 million Q1-2026 turnover with 42% growth excluding aquaculture (EPA:FALG); and Chinese food-grade Schizochytrium DHA algal oil at roughly 40% DHA content anchors the Asian supply. Rising fish-oil prices are widening the commercial opening for these algal oils.

The key directions of microalgal omega-3 are:

1. Crythecodinium DHA (Crythecodinium DHA): Crythecodinium cohnii fermentation for high-DHA algal oil (dsm-firmenich life’sDHA®) used in infant formula and supplements.
2. Nannochloropsis EPA (Nannochloropsis EPA): Nannochloropsis phototrophic cultivation for EPA-rich polar-lipid oil (Qualitas Health AlmegaPL® / iwi).
3. Schizochytrium DHA oil (Schizochytrium DHA Oil): heterotrophic Schizochytrium fermentation yielding high-concentration DHA algal oil (Kingdomway, Fermentalg ΩRIGINS).
4. Heterotrophic algae fermentation (Heterotrophic Algae Fermentation): sugar-fed fermenter cultivation (vs open ponds) for reproducible, high-density omega-3 lipid productivity.

Sectoral value chain#

[microalga strain (Crythecodinium / Nannochloropsis / Schizochytrium)] ──> [fermentation / cultivation] ──> [biomass harvest]
                                                                                      │
                                                                              (lipid accumulation)
                                                                                      │
                                                                                      ▼
[EPA/DHA algal oil ingredient] <─── [refining & standardization] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Heterotrophic fermentation (Heterotrophic Fermentation): sugar-fed dark fermenters (vs sunlit ponds) for high cell-density omega-3 lipid productivity.
• Polar-lipid EPA delivery (Polar-Lipid EPA Delivery): Nannochloropsis phospholipid/glycolipid EPA (AlmegaPL) with demonstrated absorption advantages.
• Fish-oil substitution (Fish-Oil Substitution): algal EPA/DHA displacing finite fish oil in supplements, infant formula and aquafeed as fish-oil prices rise.

02US#

The United States anchors the human-nutraceutical algal omega-3 market, building on the original Martek life’sDHA heritage and a Texas-based EPA specialist.

DSM life’sDHA heritage, Qualitas Health (iwi) EPA#

• dsm-firmenich (life’sDHA): the life’sDHA® line — originating in the US (Martek Biosciences, acquired by DSM) — is the dominant algal DHA brand for infant formula and supplements; the 2026 life’sDHA® B54-0100 variant delivers a naturally potent DHA algal oil with exceptional sensory appeal.
• Qualitas Health (iwi life, Houston): produces AlmegaPL®, a Nannochloropsis-derived EPA omega-3 lecithin; a February-2024 clinical trial showed evidence of superior omega-3 absorption versus conventional fish-oil forms.
• DSHEA market: the US dietary-supplement framework underpins the largest vegan-algal-omega-3 supplement market, driving softgel and gummy innovation.

03CN#

China is the leading Asian producer of Schizochytrium-derived algal DHA oil, though corporate-specific 2026 facts could not be cleanly source-confirmed within the capped search.

Xiamen Kingdomway, Schizochytrium DHA algal oil#

• Kingdomway (Xiamen): a publicly listed (SZ:002626) Chinese producer of Schizochytrium-derived DHA algal oil for food-grade and supplement use; the Chinese food-grade algal DHA oil stream is standardized at roughly 40% DHA content.
• Caveat: within the capped two-candidate search, both Chinese producers (Kingdomway, CABIO Biotech) returned only generic supplier-directory and product-listing pages rather than company-specific 2026 corporate news; Kingdomway is retained as a structural anchor with no invented figures.
• Regulatory frame: algal DHA/ARA ingredients for infant formula and supplements in China sit under NMPA / market-regulation oversight.

04EU#

Europe pairs the global life’sDHA leader (Netherlands) with a fast-growing French EPA/DHA producer.

DSM-Firmenich life’sDHA, Fermentalg ΩRIGINS, EU Novel Food#

• dsm-firmenich (Netherlands): the life’sDHA® / life’sOMEGA® algal-oil portfolio is the global benchmark for infant-formula and supplement EPA/DHA; the 2026 life’sDHA® B54-0100 extends the line with a high-potency, high-sensory DHA algal oil.
• Fermentalg (France, EPA:FALG): launched OMEGA ΩRIGINS™ high-EPA/DHA algal oil and a high-EPA algae omega-3 oil (2026); reported a record €3.7 million Q1-2026 turnover and 42% sales growth excluding aquaculture, citing rising fish-oil prices as a growth lever.
• EU Novel Food & EFSA: algal EPA/DHA oils in the EU are placed under the Novel Food framework and EFSA health-claim rules, framing the European infant-nutrition and supplement ingredient trade.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack pairs strain-specific fermentation with food-grade lipid refining and absorption-optimized delivery forms.

1. Crythecodinium DHA fermentation (Crythecodinium DHA):
   • Crythecodinium cohnii is grown heterotrophically to accumulate a DHA-rich lipid fraction; dsm-firmenich’s life’sDHA® is the established global output for infant-formula DHA.
   • The 2026 life’sDHA® B54-0100 variant improves the sensory profile of the high-DHA algal oil for supplement and nutrition use.
2. Nannochloropsis EPA delivery (Nannochloropsis EPA):
   • Qualitas Health grows Nannochloropsis for AlmegaPL®, an EPA delivered in polar-lipid (phospholipid/glycolipid) form that a 2024 clinical trial associated with superior omega-3 absorption.
3. Schizochytrium heterotrophic DHA oil (Schizochytrium DHA Oil):
   • Schizochytrium is fermented on sugars to yield a high-concentration DHA algal oil (Fermentalg ΩRIGINS, Kingdomway); the Chinese food-grade stream is standardized near 40% DHA content.

07Value chains and production pipelines#

Industrial pipeline of microalgal omega-3 oils (FDA DSHEA / EU Novel Food / ISO 22000)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Strain & seed          │ ───> │ 2. Fermentation           │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Oil extraction         │ <─── │ 3. Harvest & disruption   │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Refining               │ ───> │ 6. Formulation            │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Strain & seed

An axenic Crythecodinium, Nannochloropsis or Schizochytrium master culture is scaled under sterile conditions to a fermenter-ready seed; the output is a clean inoculum.

Stage 2: Fermentation / cultivation

The seed is grown in heterotrophic fermenters (sugar-fed, Crythecodinium/Schizochytrium) or photobioreactors (Nannochloropsis) to accumulate omega-3-rich lipid biomass; the output is concentrated lipid-laden biomass.

Stage 3: Harvest & disruption

The biomass is dewatered and cells are disrupted to release the intracellular lipid fraction; the output is disrupted cell mass ready for oil recovery.

Stage 4: Oil extraction

The crude algal oil is recovered from the cell mass by solvent or supercritical-CO₂ extraction; the output is crude EPA/DHA algal oil.

Stage 5: Refining

The crude oil is degummed, bleached and deodorized to a food-grade omega-3 oil standardized to its EPA/DHA content; the output is refined algal EPA/DHA oil.

Stage 6: Formulation

The refined oil is standardized and encapsulated into supplement softgels, infant-formula DHA powders and B2B nutrition ingredients under FDA DSHEA / EU Novel Food / ISO 22000 controls; the output is a marketable microalgal omega-3 product.